anx_I__cpt_4__point_20__point_c__text_1
reporting of suspected unexpected serious adverse reactions by the sponsor to the Eudravigilance database; and
← (c) · All articles · (d) →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.